
Maximize Your Wallet: Best Cards To Use With Chase Sapphire Preferred
There's a long list of attributes that make the Sapphire Preferred such a stellar product and one of the best rewards cards on the market, so let's get into it:
For all the Sapphire Preferred's strengths, there's still room for improvement. For example:
This is where pairing the Sapphire Preferred with another credit card can take your points earning to the next level.
The Chase Freedom Unlimited® is a no annual fee card with simple yet versatile rewards earning: 5% cash back on travel purchased through Chase Travel℠, 3% cash back on eligible dining and drugstores and 1.5% on all other purchases.
It's a solid card on its own, but when paired with the Sapphire Preferred, it becomes a powerful tool for maximizing every dollar you spend. What makes this pairing so effective is how well the two cards complement each other.
The Sapphire Preferred shines in categories like travel and dining, while the Freedom Unlimited picks up everything else with a minimum above-average return of 1.5X. Instead of settling for the Sapphire Preferred's underwhelming 1X on nonbonus purchases, you can route that spending through the Freedom Unlimited and boost your base earnings by 50%.
Since both cards earn Chase Ultimate Rewards® points, combining them means you not only earn more, you also unlock better redemption value through the Sapphire Preferred's 25% travel portal boost or its valuable airline and hotel transfer partners.
The no annual fee Chase Freedom Flex® brings rotating 5% bonus categories to the table, making it a trusty sidekick for your Sapphire Preferred. While it earns just 1% back on most purchases, the real value lies in its quarterly bonus categories, where you can earn 5% back on things like gas, grocery stores and online shopping. You'll earn 5% cash back on up to $1,500 in combined purchases in categories that rotate quarterly (requires activation), 5% cash back on travel purchased through Chase Travel℠, 3% cash back on dining and drugstores and 1% cash back on all other purchases.
The Sapphire Preferred doesn't offer rotating categories, so the Flex fills a valuable gap, especially if your spending habits shift throughout the year. And like the Freedom Unlimited, it earns Chase Ultimate Rewards® points that become far more valuable once moved to the Sapphire Preferred. That means you can earn 5X points on select categories and redeem those points at a boosted 1.25 cents through Chase Travel—or transfer them to travel partners for even bigger wins.
On the surface, the Sapphire Preferred and Capital One Venture X Rewards Credit Card (rates & fees) may look like competitors, but together they cover nearly every rewards gap. While the Sapphire Preferred focuses on bonus categories and point transfers, the Venture X offers flat-rate simplicity with 2X miles on every purchase—plus premium travel perks like lounge access and annual credits.
Where the Sapphire Preferred lacks luxury travel features, the Venture X delivers: Partner Lounge Network access, Capital One Lounge access and a $300 annual travel credit for bookings through Capital One Travel. That travel credit, plus a 10,000-mile anniversary bonus, help make up for the $395 annual fee (rates & fees). Access to Capital One's transfer partners means you have even more options when it's time to book your dream trip.
If you don't mind managing two issuers, this duo gives you premium travel perks, solid base earnings on every purchase and access to two of the most valuable rewards ecosystems.
The Chase Sapphire Preferred® Card is an impressive standalone travel card, but it becomes far more powerful when paired with the right partner—or two. Whether you want to earn more on everyday spending, take advantage of rotating bonus categories or enjoy premium travel perks, combining it with cards like the Freedom Unlimited, Freedom Flex or Venture X can help you earn more, redeem better and get the most from every dollar.
Find the best Chase credit card for your needs.
As long as you pay your cards on time, avoid carrying a balance and practice good credit habits, having multiple credit cards will not negatively impact your credit score. It can even help your score over time.
You don't have to stop at two cards to maximize your rewards and benefits. Take the Chase Trifecta, for example, where you can combine some of Chase's best cards, like the Chase Sapphire Reserve® or Preferred, with the Chase Freedom Flex and Chase Freedom Unlimited. Having a premium Ultimate Rewards card paired with no-annual-fee cash-back cards can unlock better earnings and more valuable redemption options.
Chase doesn't publish the exact score needed to be eligible for the Sapphire Preferred, but as a premium credit card, you'll need at least a good credit score (at least 670 on the FICO scoring scale).
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Hill
5 hours ago
- The Hill
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month's supply of Novo Nordisk's semaglutide pen products for $499 through GoodRx. The list price for a monthly supply of a product like Ozempic is normally around $1,000 or more without insurance. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' GoodRx CEO and President Wendy Barnes said in a statement. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them,' added Barnes. 'It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' This is the most recent in similar moves Novo Nordisk has made to make its popular diabetes and weight loss medication more widely available. Earlier this year, the company announced a direct-to-patient program called NovoCare® Pharmacy for uninsured and underinsured individuals who can pay $499 a month for Wegovy. Novo Nordisk also partnered with online telehealth companies like Ro and LifeMD to sell its pens at the same price point. The telehealth company Hims & Hers was also originally included in the partnership, but Novo Nordisk ended it after accusing the company of illegally selling compounded versions of semaglutide. Hims & Hers maintains it is providing personalized, compounded products within regulatory guidelines. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' Dave Moore, executive vice president of U.S. operations of Novo Nordisk, said in a statement. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic® self-pay offer for type 2 diabetes patients at an unprecedented price.' Sen. Bernie Sanders (I-Vt.), a prominent critic of high drug costs, called the announcement a 'modest step forward.' 'Novo Nordisk's move to cut the price of Ozempic to $499 for the uninsured is a modest step forward, but let's not forget,' Sanders said on the social media platform X. 'Ozempic costs just $59 in Germany while it costs less than $5 to make. The U.S. must no longer pay the highest prices in the world for prescription drugs.

Business Wire
5 hours ago
- Business Wire
Levi Strauss & Co. Appoints Chris Callieri as Chief Supply Chain Officer
SAN FRANCISCO--(BUSINESS WIRE)--Levi Strauss & Co. (LS&Co., NYSE: LEVI) today announced the appointment of Chris Callieri as senior vice president and chief supply chain officer, effective September 15. Reporting to Michelle Gass, president and chief executive officer, Callieri will join the company's executive leadership team and will be responsible for the global supply chain operations for the Levi's® brand. His responsibilities include product development, sourcing, global supply management, sustainability, and distribution and logistics. 'We're excited to welcome Chris to LS&Co. at this pivotal moment in our evolution into a DTC-first denim lifestyle company," said Gass. "With a proven track record of delivering results at scale, he's the right leader to strengthen our end-to-end supply chain agility, drive innovation, and advance our sustainability goals — all while delivering exceptional value to our fans worldwide. " Callieri brings more than 20 years of international supply chain experience in the retail and consumer goods industries. He joins LS&Co. from Victoria's Secret & Co., where he served as chief supply chain officer, leading a global team across multiple geographies and overseeing product development, sourcing, production, and distribution and logistics for various categories including intimates, apparel, accessories and beauty. Previously he was at Tory Burch, where he was pivotal in implementing systems like PLM, Merchandise Planning and SAP, and led the transformation of the supply chain. Chris has a long-standing commitment to sustainability and established Tory Burch's sustainability team and strategy. Prior to Tory Burch, Callieri held senior roles at Adidas, including senior vice president, product operations, where he was responsible for materials development, product development, sourcing and logistics for Adidas Lifestyle Brands. Callieri's extensive experience also includes leadership roles at HRC Advisory and A.T. Kearney, where he led various transformation initiatives and developed strategies to improve supply chain responsiveness and product innovation for leading retailers. 'I'm thrilled to join LS&Co. at such an exciting time for the iconic Levi's® brand, a true category leader that thrives at the center of culture," Callieri said. "I look forward to working with the talented LS&Co. team to deliver strong performance, serve our fans around the world, and strengthen Levi's® position as the world's definitive denim lifestyle brand." About Levi Strauss & Co. Levi Strauss & Co. (LS&Co.) is one of the world's largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's®, Levi Strauss Signature™ and Beyond Yoga® brands. Its products are sold in approximately 120 countries worldwide through a combination of chain retailers, department stores, online sites, and a global footprint of approximately 3,400 retail stores and shop-in-shops. Levi Strauss & Co.'s reported 2024 net revenues were $6.4 billion. For more information, go to and for financial news and announcements go to
Yahoo
5 hours ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data



